Clinical Trial
2025-520665-47-00 Recruiting, Active
NYRVANA
An Open-Label Dose Escalation Study to Assess the Safety and Tolerability of a Single Intravitreal Injection of SPVN20 Gene Therapy in Subjects with No Light Perception Due to End Stage Rod Cone Dystrophy, and Who Retain Dormant Foveal Cone Photoreceptors
Disease
Disease type
Retinitis Pigmentosa
Patient type
Adult
Children
Funding
Industry
Members involved
Main investigators
Pr Bart LEROY
Representative
Belgium
Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
Pr Isabelle Audo
Representative
France
Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
ERN EYE member investigating site
HCP : Principal investigators
RÉFÉRET National Hospital of Ophthalmology of Quinze-Vingts, Paris, France
Adress
28 Rue de Charenton
75012 Paris
France
Ghent University Hospital, Ghent, Belgium
Adress
Corneel Heymanslaan 10
9000 Ghent
Belgium